Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort

Lupus

Volumn 27, Issue 4, 2018, Pages 536-544

  Ugarte Gil, M F ^a,b   Wojdyla, D ^c   Pastor Asurza, C A ^a,d   Gamboa Cardenas R V ^a   Acevedo Vasquez E M ^a,d   Catoggio, L J ^e   Garcia M A ^f   Bonfa E ^g   Sato, E I ^h   Massardo, L ⁱ   Pascual Ramos, V ^j   Barile, L A ^k   Reyes Llerena, G ^l   Iglesias Gamarra, A ^m   Molina Restrepo, J F ⁿ   Chacon Diaz R ^o   Alarcon G S ^p   Pons Estel, B A ^q  

^a HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN   (Peru)

^b UNIVERSIDAD CIENTÍFICA DEL SUR   (Peru)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f Hospital Interzonal General de Agudos de La Plata   (Argentina)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^j INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^k INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^l Medical Surgical Research Center   (Cuba)

^m UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

ⁿ UNIVERSIDAD CES   (Colombia)

^o HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^p University of Alabama at Birmingham   (United States)

^q Hospital Provincial de Rosario   (Argentina)

more..

Author keywords

antimalarials; flares; risk factors; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; ANTIMALARIAL AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SLEDAI; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; AGE; CLINICAL TRIAL; EPIDEMIOLOGY; ETHNOLOGY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROTECTION; REMISSION; SOUTH AND CENTRAL AMERICA; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIMALARIALS; CASE-CONTROL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LATIN AMERICA; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROTECTIVE FACTORS; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85044409024     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317728810     Document Type: Article

References (37)

1. Ruperto N, Hanrahan LM, Alarcón GS, International consensus for a definition of disease flare in lupus. Lupus 2011; 20: 453–462.
2. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000; 27: 377–379.
3. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685–691.
4. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.
5. Symmons DP, Coppock JS, Bacon PA, Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988; 69: 927–937.
6. Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: Characteristics and predictors of outcome. Lupus 2003; 12: 672–676.
7. Bandeira M, Buratti S, Bartoli M, Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006; 15: 515–520.
8. Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Ann Rheum Dis 2015; 74: 1019–1023.
9. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study. Rheumatology (Oxford) 2004; 43: 1039–1044.
10. Narayanan S, Wilson K, Ogelsby A, Juneau P, Durden E. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med 2013; 55: 1262–1270.
11. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1159–1167.
12. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol 2010; 37: 568–573.
13. Pollard C, Hartz S, Leage SL, Paget MA, Cook J, Enstone A. Elicitation of health state utilities associated with varying severities of flares in systemic lupus erythematosus. Health Qual Life Outcomes 2015; 13: 66–66.
14. Inês L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JA. Identification of clinical predictors of flare in systemic lupus erythematosus patients: A 24-month prospective cohort study. Rheumatology (Oxford) 2014; 53: 85–89.
15. Zen M, Bassi N, Nalotto L, Disease activity patterns in a monocentric cohort of SLE patients: A seven-year follow-up study. Clin Exp Rheumatol 2012; 30: 856–863.
16. Cervera R, Doria A, Amoura Z, Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev 2014; 13: 621–629.
17. Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. Lupus 2010; 19: 239–246.
18. Petri M, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: A prospective study. J Rheumatol 2009; 36: 2476–2480.
19. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003; 42: 1372–1379.
20. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 1316–1319.
21. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–154.
22. Petri MA, van Vollenhoven RF, Buyon J, Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65: 2143–2153.
23. Tan EM, Cohen AS, Fries JF, The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
24. Pons–Estel BA, Catoggio LJ, Cardiel MH, The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: Ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 2004; 83: 1–17.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.
26. Gladman D, Ginzler E, Goldsmith C, The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.
27. Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1152–1158.
28. Conti F, Ceccarelli F, Perricone C, Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: A 2-year follow-up study. PLoS One 2012; 7: e45934–e45934.
29. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634–643.
30. Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev 2016; 15: 656–663.
31. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55: 900–904.
32. Shinjo SK, Bonfá E, Wojdyla D, Antimalarial treatment may have a time–dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62: 855–862.
33. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010; 69: 20–28.
34. Alarcón GS, McGwin G, Bertoli AM, Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168–1172.
35. Costedoat-Chalumeau N, Galicier L, Aumaître O, Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013; 72: 1786–1792.
36. Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: A longitudinal cohort analysis. Arthritis Care Res (Hoboken) 2016; 68: 1295–1302.
37. Henderson LK, Masson P, Craig JC, Induction and maintenance treatment of proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61: 74–87.